Wellington Fernandes Silva

Dr. Wellington Fernandes Silva

Hematology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
Wellington Fernandes SilvaWellington Fernandes Silva
Wellington Fernandes Silva
LRLidiane Inês da Rosa
Lidiane Inês da Rosa
GMGabriel Lacerda Marquez
Gabriel Lacerda Marquez
LBLucas Bassolli
Lucas Bassolli
LTLuciana Tucunduva
Luciana Tucunduva
EVElvira D.R.P. Velloso
Elvira D.R.P. Velloso

9 November 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
KLKeli Lima
Keli Lima
DPDiego A Pereira-Martins
Diego A Pereira-Martins
LMLívia Bassani Lins de Miranda
Lívia Bassani Lins de Miranda
JCJuan Luiz Coelho-Silva
Juan Luiz Coelho-Silva
GLGiovana da Silva Leandro
Giovana da Silva Leandro
JMJoão Agostinho Machado-Neto
João Agostinho Machado-Neto
The treatment of acute leukemia is challenging because of the genetic heterogeneity between and within patients. Leukemic stem cells (LSCs) are relatively drug-resistant and frequently relapse. Their plasticity and capacity to adapt to extracellular stress, in which mitochondrial metabolism and autophagy play important roles, further complicates treatment. Genetic models of phosphatidylinositol-5-phosphate 4-kinase type 2 protein (PIP4K2s) inhibition have demonstrated the relevance of these enzymes in mitochondrial homeostasis and autophagic flux. Here, we uncovered the cellular and molecular effects of THZ-P1-2, a pan-inhibitor of PIP4K2s, in acute leukemia cells. THZ-P1-2 reduced cell viability and induced DNA damage, apoptosis, loss of mitochondrial membrane potential, and the accumulation of acidic vesicular organelles. Protein expression analysis revealed that THZ-P1-2 impaired autophagic flux. In addition, THZ-P1-2 induced cell differentiation and showed synergistic effects with venetoclax. In primary leukemia cells, LC-MS/MS-based proteome analysis revealed that sensitivity to THZ-P1-2 is associated with mitochondrial metabolism, cell cycle, cell-of-origin (hematopoietic stem cell and myeloid progenitor), and the TP53 pathway. The minimal effects of THZ-P1-2 observed in healthy CD34+cells suggest a favorable therapeutic window. Our study provides insights into the pharmacological inhibition of PIP4K2s targeting mitochondrial homeostasis and autophagy, shedding light on a new class of drugs for acute leukemia.

1 June 2018 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
Wellington Fernandes SilvaWellington Fernandes Silva
Wellington Fernandes Silva
AMAndrezza Bertolaci Medina
Andrezza Bertolaci Medina
PYPatrícia Eiko Yamakawa
Patrícia Eiko Yamakawa
VBValéria Buccheri
Valéria Buccheri
EVElvira Deolinda Rodrigues Pereira Velloso
Elvira Deolinda Rodrigues Pereira Velloso
VRVanderson Rocha
Vanderson Rocha

21 October 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
FMFernanda Rodrigues Mendes
Fernanda Rodrigues Mendes
Wellington Fernandes SilvaWellington Fernandes Silva
Wellington Fernandes Silva
RMRaphael da Costa Bandeira de Melo
Raphael da Costa Bandeira de Melo
DSDouglas Rafaele Almeida Silveira
Douglas Rafaele Almeida Silveira
EVElvira Deolinda Rodrigues Pereira Velloso
Elvira Deolinda Rodrigues Pereira Velloso
EREduardo Rego
Eduardo Rego

26 May 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
DSDouglas Silveira
Douglas Silveira
LQLynn Quek
Lynn Quek
ISItamar Santos
Itamar Santos
ACAnna Corby
Anna Corby
JCJuan L. Coelho-Silva
Juan L. Coelho-Silva
VRVanderson Geraldo Rocha
Vanderson Geraldo Rocha
The 2017 European LeukemiaNet 2017 acute myeloid leukemia (AML) risk stratification (ELN2017) is widely used for risk-stratifying patients with AML. However, its applicability in low- and middle-income countries is limited because of a lack of full cytogenetic and molecular information at diagnosis. Here, we propose an alternative for risk stratification (the Adapted Genetic Risk [AGR]), which permits cytogenetic or molecular missing data while retaining prognostic power. We first analyzed 167 intensively treated patients with nonacute promyelocytic leukemia AML enrolled in São Paulo, Brazil (Faculdade de Medicina da Universidade de São Paulo), as our training data set, using ELN2017 as the standard for comparison with our AGR. Next, we combined our AGR with clinical prognostic parameters found in a Cox proportional hazards model to create a novel scoring system (survival AML score, SAMLS) that stratifies patients with newly diagnosed AML. Finally, we have used 2 independent test cohorts, Faculdade de Medicina de Ribeirão Preto (FMRP; Brazil, n = 145) and Oxford University Hospitals (OUH; United Kingdom, n = 157) for validating our findings. AGR was statistically significant for overall survival (OS) in both test cohorts (FMRP, P = .037; OUH, P = .012) and disease-free survival in FMRP (P = .04). The clinical prognostic features in SAMLS were age (>45 years), white blood cell count (30.0 × 103/μL), and low albumin levels (<3.8 g/dL), which were associated with worse OS in all 3 cohorts. SAMLS showed a significant difference in OS in the training cohort (P < .001) and test cohorts (FMRP, P = .0018; OUH, P < .001). Therefore, SAMLS, which incorporates the novel AGR evaluation with clinical parameters, is an accurate tool for AML risk assessment.

17 November 2018 in Journal of Chemotherapy
Verified
Journal Article
Closed access
Wellington Fernandes SilvaWellington Fernandes Silva
Wellington Fernandes Silva
LRLidiane Inês da Rosa
Lidiane Inês da Rosa
MBMarcelo Belesso
Marcelo Belesso
LLLuís Alberto Lage
Luís Alberto Lage
VRVanderson Rocha
Vanderson Rocha
JPJuliana Pereira
Juliana Pereira
While Burkitt lymphoma (BL) is an aggressive subtype of non-Hodgkin lymphoma more prevalent in tropical areas, few studies on BL have been conducted in Latin America. Here, we evaluate the clinical presentation and outcomes of an adapted LMB regimen for adults with sporadic BL. We retrospectively evaluated hospital records from University of São Paulo (USP) between 1999 and 2017. Thirty-six patients were included, the median age was 33.5 years and 69% (25) were male. Most patients presented advanced stage disease (81%), 8% had CNS disease, and the majority belonged to LMB group B (75% (27)). Three patients died during the induction phase, and the remaining patients (33) achieved complete response. There was one relapse over a median follow-up of 6 years. Overall survival estimated at 5 years was 89%. We conclude that an adapted LMB protocol is safe and feasible in Brazil.